Nova Minerals NVA
Three insiders bought $47K over 11 days, within the 30-day window
Last open-market buy
- Christopher Gerteisen $22K
- Joshua I. Girnun $20K
- Avi Geller $5K
Form 4
Insider buys and sales, small caps first
Source: Form 4 filings on SEC EDGAR
Type a ticker for one company's Form 4s, or read today's open-market trades at companies with a public float under $300M (All companies is one tap away): buys first, then sales, cluster buys and each insider's record across companies.
Open-market buys, last day2
Cluster buys, last 30 days, under $300M float1
Open-market sales, last day5
Planned sales (10b5-1), last day0
Insiders you follow
Cluster buys, last 30 days, under $300M float
Companies whose last cluster buy was in the last 30 days.
Trades filed since Nov 3
Notes on each row are as each Form 4 states them, next to SEC Tracker's own records of the company's filings and other insiders' buys. The Stake column is the change in their holding.
| Traded | Company | Insider | Trade | Value | Stake | Notes |
|---|---|---|---|---|---|---|
| Nov 2, 2026 Filed Nov 3, 2026 | ProMIS Neurosciences PMN | Neil Cashman Chief Scientific Officer | Open-market buy 10,000 shares | $39K at $3.86 | +221% | Their first open-market buy here in SEC Tracker's records. 80 days after the company's SCHEDULE 13G/A filed Aug 14, 2026. |
| Oct 30, 2026 Filed Nov 3, 2026 | ProMIS Neurosciences PMN | Eugene Williams Director | Open-market buy 1,316 shares | $5K at $3.99 | +11% | Their first open-market buy here in SEC Tracker's records. 77 days after the company's SCHEDULE 13G/A filed Aug 14, 2026. |
| Nov 2, 2026 Filed Nov 3, 2026 | Replimune Group REPL | Kapil Dhingra Director | Open-market sale 21,500 shares | $409K at $19.00 | −50% | The filing does not mark this sale as under a Rule 10b5-1 plan. The same day as a Form 144 notice of a planned insider sale filed Nov 2, 2026. |
| Nov 2, 2026 Filed Nov 3, 2026 | Artiva Biotherapeutics ARTV | Fred Aslan CEO | Open-market sale 62,178 shares | $260K at $4.18 | −4% | The filing does not mark this sale as under a Rule 10b5-1 plan. 6 days after the company's 8-K filed Oct 27, 2026. |
| Nov 2, 2026 Filed Nov 3, 2026 | Artiva Biotherapeutics ARTV | Christopher Horan Officer | Open-market sale 10,423 shares | $44K at $4.18 | −3% | The filing does not mark this sale as under a Rule 10b5-1 plan. 6 days after the company's 8-K filed Oct 27, 2026. |
| Nov 2, 2026 Filed Nov 3, 2026 | Artiva Biotherapeutics ARTV | Jennifer Bush Officer | Open-market sale 8,439 shares | $35K at $4.18 | −2% | The filing does not mark this sale as under a Rule 10b5-1 plan. 6 days after the company's 8-K filed Oct 27, 2026. |
| Nov 2, 2026 Filed Nov 3, 2026 | Artiva Biotherapeutics ARTV | Subhashis Banerjee Chief Medical Officer | Open-market sale 1,110 shares | $5K at $4.18 | −1% | The filing does not mark this sale as under a Rule 10b5-1 plan. 6 days after the company's 8-K filed Oct 27, 2026. |
Insider records
The 7 insiders in these trades with the most bought and sold on the open market across every company, in SEC Tracker's records.
| Insider | Buys | Sales | Bought | Sold | Companies |
|---|---|---|---|---|---|
| Fred Aslan | 0 | 2 | $413K | 1 | |
| Kapil Dhingra | 0 | 1 | $409K | 1 | |
| Christopher Horan | 0 | 1 | $44K | 1 | |
| Neil Cashman | 1 | 0 | $39K | 1 | |
| Jennifer Bush | 0 | 1 | $35K | 1 | |
| Eugene Williams | 1 | 0 | $5K | 1 | |
| Subhashis Banerjee | 0 | 1 | $5K | 1 |
Open-market trades are Form 4 transaction codes P (purchase) and S (sale). Planned sales are those the filing marks as made under a Rule 10b5-1 plan. A P-code buy at the offering price within a day of the company's FWP, 424B prospectus or offering 8-K is marked Bought in the offering and left out of open-market buy counts and cluster buys. Prices and values are as stated in each Form 4. Stock prices aren't shown on this page. Not investment advice.